CN1890252A - 新类型的γδT细胞活化剂及其应用 - Google Patents

新类型的γδT细胞活化剂及其应用 Download PDF

Info

Publication number
CN1890252A
CN1890252A CNA2004800356576A CN200480035657A CN1890252A CN 1890252 A CN1890252 A CN 1890252A CN A2004800356576 A CNA2004800356576 A CN A2004800356576A CN 200480035657 A CN200480035657 A CN 200480035657A CN 1890252 A CN1890252 A CN 1890252A
Authority
CN
China
Prior art keywords
group
cell
compound
cells
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800356576A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯蒂安·贝尔曼特
帕特里斯·努雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2003/006375 external-priority patent/WO2004050096A2/en
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of CN1890252A publication Critical patent/CN1890252A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65502Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a three-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2404Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2425Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic containing the structure (RX)(RR'N)P(=Y)-Z-(C)n-Z'-P(=Y)(XR)2 (X = O, S, NR; Y = O, S, electron pair; Z = O, S; Z' = O, S)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2404Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2433Compounds containing the structure N-P(=X)n-X-acyl, N-P(=X)n-X-heteroatom, N-P(=X)n-X-CN (X = O, S, Se; n = 0, 1)
    • C07F9/245Compounds containing the structure N-P(=X)n-X-acyl, N-P(=X)n-X-heteroatom, N-P(=X)n-X-CN (X = O, S, Se; n = 0, 1) containing the structure N-P(=X)n-X-P (X = O, S, Se; n = 0, 1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2454Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2454Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2462Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of unsaturated acyclic amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65502Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a three-membered ring
    • C07F9/65505Phosphonic acids containing oxirane groups; esters thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
CNA2004800356576A 2003-12-02 2004-12-02 新类型的γδT细胞活化剂及其应用 Pending CN1890252A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/IB2003/006375 WO2004050096A2 (en) 2002-12-02 2003-12-02 Phosphoantigens for regulating an immune response
WOPCT/IB2003/006375 2003-12-02
US57923704P 2004-06-15 2004-06-15
US60/579,237 2004-06-15

Publications (1)

Publication Number Publication Date
CN1890252A true CN1890252A (zh) 2007-01-03

Family

ID=34655260

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800356576A Pending CN1890252A (zh) 2003-12-02 2004-12-02 新类型的γδT细胞活化剂及其应用

Country Status (8)

Country Link
US (1) US7767842B2 (https=)
EP (1) EP1689758A2 (https=)
JP (1) JP2007516244A (https=)
CN (1) CN1890252A (https=)
AU (1) AU2004295194A1 (https=)
BR (1) BRPI0417088A (https=)
CA (1) CA2547008A1 (https=)
WO (1) WO2005054258A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212666D0 (en) 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
JP2007534743A (ja) 2004-04-26 2007-11-29 イネイト・ファーマ アジュバント組成物およびその使用方法
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
EP1933848A2 (en) * 2005-10-06 2008-06-25 Innate Pharma Phosphoantigen salts of organic bases and methods for their crystallization
WO2007057440A2 (en) * 2005-11-17 2007-05-24 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
EP1878440A1 (en) * 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
US20100029674A1 (en) 2006-11-17 2010-02-04 Innate Pharma, S.A. Methods of Using Phosphoantigen for the Treatment of Cancer
EP2123285A1 (en) * 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021452A2 (en) * 1995-12-14 1997-06-19 Advanced Magnetics, Inc. Macromolecular prodrugs of nucleotide analogs
DE19815864A1 (de) * 1998-04-08 1999-10-14 Europ Lab Molekularbiolog 5'-modifizierte Nukleotide und ihre Anwendung in der Molekularbiologie und Medizin
ATE431428T1 (de) 1998-10-01 2009-05-15 Variagenics Inc Ein verfahren zur analyse von polynukleotiden
WO2000036151A1 (en) 1998-12-14 2000-06-22 Li-Cor, Inc. A heterogeneous assay for pyrophosphate detection
FR2791981B1 (fr) * 1999-04-06 2001-07-20 Inst Nat Sante Rech Med Composes inhibant selectivement les lymphocytes tgamma9delta2, et leurs applications
DE10201458A1 (de) 2001-04-11 2002-10-17 Adelbert Bacher Intermediate und Enzyme des Mevalonat-unabhängigen Isoprenoidbiosyntheseweg
ATE411805T1 (de) * 2001-07-20 2008-11-15 Bioagency Ag Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
FR2833266B1 (fr) * 2001-12-11 2004-10-22 Mayoly Spindler Lab Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
DE60233576D1 (de) * 2002-12-02 2009-10-15 Innate Pharma Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
ITMI20060366A1 (it) 2006-03-01 2007-09-02 C4T S C A R L Composti organo tiopirosfosfati metodo per prepararli e composizioni che li contengono

Also Published As

Publication number Publication date
AU2004295194A1 (en) 2005-06-16
US7767842B2 (en) 2010-08-03
US20070249565A1 (en) 2007-10-25
EP1689758A2 (en) 2006-08-16
JP2007516244A (ja) 2007-06-21
BRPI0417088A (pt) 2007-03-13
WO2005054258A3 (en) 2006-03-09
WO2005054258A2 (en) 2005-06-16
CA2547008A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
CN1216060C (zh) 膦酸酯核苷酸化合物
CN1434795A (zh) 带官能化辅助支链的酰化假二肽
EP3057956B1 (en) Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
US20100222306A1 (en) Class of Gamma Delta T Cells Activators and Use Thereof
CN1353719A (zh) 新的含磷前药
CN1890252A (zh) 新类型的γδT细胞活化剂及其应用
CN1239964A (zh) 四膦酸酯二环三酸酐
HK1047939A1 (en) Water soluble prodrugs of hindered alcohols or phenols
CN1190401A (zh) C-4′修饰的腺苷激酶抑制剂
CN1045395A (zh) 2′-脱氧-5-氟尿苷衍生物和其制法
CN1526016A (zh) 稳定核酸的方法
CN1346360A (zh) 作为抗病毒剂的(1r,顺式)-4-(6-氨基-9h-嘌呤-9-基)-2-环戊烯-1-甲醇的氨基磷酸酯及一二和三磷酸酯
CN88102932A (zh) 新的嘌呤取代的氧杂环丁烷类化合物
CN1023561C (zh) 新颖的隐陡头霉素/腺苷衍生物的制备方法
CN1217335A (zh) 制备前体药的方法
CN1533397A (zh) 具有抗病毒活性的6-2'-(膦酰基甲氧基)烷氧基嘧啶衍生物
CN1121707A (zh) 用作抗癌剂和抗原生动物剂的不饱和氨基化合物
CN1198656C (zh) 2′,5′-寡聚腺苷酸的双重作用抗病毒衍生物及其应用
CN88100826A (zh) 核苷酸类似物的生产及其使用
CN1910193A (zh) 核糖核酸化合物及低聚核酸化合物的液相合成法
US20100291118A1 (en) Class of Gamma Delta T Cells Activators and Use Thereof
MXPA06006327A (en) New class of gamma delta t cells activators and use thereof
CN1733779A (zh) 新的含磷前药
CN1154112A (zh) 二核苷-5',5'-焦磷酸酯
HK1007881A1 (en) Sugar modified nucleosides and their use for synthesis of oligonucleotides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070103